



Test information is available on our website:
PreventionGenetics.com

PREVENTION GENETICS USE ONLY

**All testing must be ordered
by a qualified Healthcare Provider**



A completed online order **OR**
paper TRF and labeled specimen
is required to initiate testing.

WHOLE EXOME SEQUENCING PGxome® TEST REQUISITION

ORDERING CHECKLIST

- ☐ Patient and comparator (if provided) specimens
- ☐ Healthcare Provider Statement
(required for specimens collected in NY)

- ☐ Clinical Features Checklist (preferred, see pages 6-10) and/or relevant medical records and family health history (i.e. clinic notes, prior genetic testing, pedigree) **(required for Diagnostic, Rapid, and Prenatal PGxome)**

PERSON COMPLETING FORM	CONTACT (DIRECT PHONE OR EMAIL)	DATE OF REQUEST (MM/DD/YYYY)
------------------------	---------------------------------	------------------------------

PATIENT INFORMATION

LAST (FAMILY) NAME		FIRST NAME		MI	DATE OF BIRTH (MM/DD/YYYY)	
ADDRESS			CITY	STATE/PROVIDENCE		ZIP / POSTAL CODE
EMAIL		PHONE NUMBER		GEOANCESTRY / ETHNICITY		
MEDICAL RECORD NUMBER (MRN)		BIOLOGICAL SEX ☐ Male ☐ Female ☐ Other, specify karyotype _____				

REASON FOR TEST ☐ Diagnosis / Affected ☐ Presymptomatic / At Risk ☐ Carrier Testing / Unaffected		ONGOING PREGNANCY ☐ NO ☐ YES	
HAS PATIENT BEEN TESTED PREVIOUSLY AT PreventionGenetics? ☐ No ☐ Yes, PG ID# _____		BLOOD TRANSFUSION ☐ NO ☐ Within last 6 weeks, include date and type DATE (MM/DD/YYYY) _____ TYPE _____	
		BONE MARROW TRANSPLANT ☐ NO ☐ Yes, include date DATE (MM/DD/YYYY) _____	

HAS PATIENT'S RELATIVE BEEN TESTED? ☐ NO ☐ YES - at PreventionGenetics, include:

RELATIVE'S NAME AND/OR PreventionGenetics ID NUMBER	DATE OF BIRTH (MM/DD/YYYY)	RELATIONSHIP TO PATIENT
---	----------------------------	-------------------------

ICD-10 CODES
(REQUIRED FOR INSURANCE BILLING) 1 PRIMARY _____ 2 _____ 3 _____

SPECIMEN INFORMATION

SPECIMEN SOURCE ☐ Whole Blood ☐ Direct CVS ☐ Tissue, Source _____ ☐ Saliva ☐ Direct Amniotic Fluid ☐ Extracted DNA, Source _____ ☐ Buccal ☐ Cultured Cells, Source _____ ☐ Other _____		SPECIMEN COLLECTION DATE (MM/DD/YYYY) If no collection date is provided, date of receipt will be used.	☐ SPECIMEN COLLECTED IN NEW YORK STATE Include New York State Genetic Testing Healthcare Provider Statement and New York State Non-Permitted Laboratory Test Reciprocity approval letter if test is not NY state approved. For a list of NY state approved tests, see website .
---	--	--	--

PATIENT TEST SELECTION

STANDARD DIAGNOSTIC PGxome		SECONDARY (ADDITIONAL) FINDINGS	COMMENTS OR SPECIAL INSTRUCTIONS:
☐ PATIENT ONLY Test Code 5000 FAMILY ☐ DUO Test Code 5200 ☐ TRIO Test Code 5300 ☐ OTHER Specify _____ Complete a <i>Comparator Test Requisition form</i> for each family member. Clinical information is REQUIRED for each comparator for accurate interpretation. ☐ Include family/comparator demographics (name, DOB, ID#, and relationship) on the proband report.	Details can be found in the PGxome Healthcare Provider Statement. Options for reporting of Secondary Findings are to be marked below. ☐ OPT IN: GUIDELINE RECOMMENDED GENES TRIO (WITH PARENTS) ONLY ☐ OPT IN: PG DISCOVERY	☐ RE-ANALYSIS Re-analysis of proband and/or family samples for additional findings.	
	OPTIONAL SECONDARY FINDINGS ADD-ON Details can be found in the PGxome Healthcare Provider Statement. Marking one or both of the options below will add an additional \$590 USD to your order. ☐ OPT IN: OTHER PREDISPOSITIONS / DIAGNOSES ☐ OPT IN: CARRIER STATUS		

RAPID DIAGNOSTIC PGxome		NO SECONDARY FINDING OPTIONS AVAILABLE FOR RAPID PGXOME	Re-analysis will be completed with original secondary finding selections unless otherwise specified. Changes to secondary finding opt ins or structure of the analysis (additional comparators) may result in additional charges. See our website
☐ PATIENT ONLY Test Code 13001		☐ Include family/comparator demographics (name, DOB, ID#, and relationship) on the proband report.	
☐ FAMILY - DUO, TRIO, ETC Codes Duo-13002 / Trio-13003 Complete a <i>Comparator Test Requisition form</i> for each family member. Clinical information is REQUIRED for each comparator for accurate interpretation.			

HEALTH SCREEN PGxome		SECONDARY (ADDITIONAL) FINDINGS	
☐ PATIENT ONLY Test Code 4000 <i>Includes carrier status.</i>	Details can be found in the PGxome Healthcare Provider Statement. Options for reporting of Secondary Findings are to be marked below. ☐ OPT IN: GUIDELINE RECOMMENDED GENES ☐ OPT IN: OTHER PREDISPOSITIONS / DIAGNOSES		for full re-analysis policy. Test Code _____ Desired secondary findings (choose opt ins at left)

ADDITIONAL COMPARATORS Complete for PGxome Family Duo or Trio orders

Please submit a separate completed diagnostic or health screen test requisition to request a full analysis of the comparator data for an additional charge, if desired.

NAME (LAST, FIRST)	DATE OF BIRTH (MM/DD/YYYY)	SAMPLE TYPE	RELATIONSHIP TO PROBAND	AFFECTED?*
				☐ NO ☐ YES
				☐ NO ☐ YES

*If YES, must include clinical info.

PATIENT	
LAST NAME	
FIRST NAME	MI

PROVIDER / LABORATORY CONTACT AND REPORTING***Our preferred method of report transmission is uploading to our secure web portal, myPrevent.*****Please provide an email address, when possible. If you have additional specific reporting requests, indicate them BELOW.****PROVIDER INFORMATION**

INSTITUTION

ADDRESS		CITY	STATE	ZIP
REQUESTING PHYSICIAN (First, Last, Degree)		REQUESTING GENETIC COUNSELOR OR ALLIED PROVIDER (First, Last, Degree)		
EMAIL ADDRESS (For report access via myPrevent)		EMAIL ADDRESS (For report access via myPrevent)		
PHONE NUMBER	NPI# (US only)	PHONE NUMBER	NPI# (US only)	

IF YOU REQUIRE REPORTS TO BE TRANSMITTED VIA ANOTHER SECURE METHOD, SPECIFY HERE.

As the ordering Healthcare Provider, I certify that: (1) I have obtained the patient's informed consent and family member's informed consent (as applicable) to perform this test as documented on a signed consent form that complies with applicable law and is consistent, in all material respects, with PreventionGenetics' Informed Consent form (available at <https://assets.preventiongenetics.com/documents/patient-informed-consent.pdf>), which I will maintain on file and make available to PreventionGenetics upon request; (2) The patient and their family member (as applicable) have been appropriately counseled and understand the risks, benefits, and limitations of this genetic testing and the implications of the results; and (3) I have received the patient's and family member's (as applicable) consent for PreventionGenetics to use and disclose information, test results, and sample as described in the consent form.

SEND OUT LABORATORY**COMPLETE ONLY IF REPORT IS NEEDED**

INSTITUTION / CONTACT

ADDRESS	CITY	STATE	ZIP
EMAIL ADDRESS (For report access via myPrevent)	PHONE NUMBER	NPI# (where applicable)	

IF YOU REQUIRE REPORTS TO BE TRANSMITTED VIA ANOTHER SECURE METHOD, SPECIFY HERE.

ADDITIONAL ACCESS TO REPORTS List additional Healthcare Providers and their emails to allow access to reports

INSTITUTION BILLING**PATIENT TESTING WILL PROCEED WHEN ALL BILLING INFORMATION HAS BEEN RECEIVED.****IF INSTITUTIONAL BILLING IS SELECTED, PAGE 8 IS NOT REQUIRED.**☐ Send invoice to the contact information above. Please provide PO number below if applicable.

BILLING INSTITUTION		PO NUMBER	
CONTACT	PHONE NUMBER	EMAIL	
ADDRESS	CITY	STATE	ZIP
BILLING ACCOUNT NUMBER ☐ UPDATED INFO	ACCESS TO TEST REPORT(S) FOR BILLING		
☐ EMAIL ADDRESS (For report access via myPrevent) _____			
☐ OTHER (specify) _____			

PATIENT	
LAST NAME	
FIRST NAME	MI

COMPLETE THIS FORM FOR PATIENT PAY AND/OR INSURANCE BILLING

PATIENT TESTING WILL PROCEED WHEN ALL BILLING INFORMATION HAS BEEN RECEIVED.

**** THIS SECTION MUST BE FILLED OUT COMPLETELY ****

RESPONSIBLE PARTY'S NAME (MUST BE 18 YEARS OR OLDER)		PHONE NUMBER	
ADDRESS	CITY	STATE	ZIP
EMAIL			

ACCEPTANCE of financial responsibility for genetic testing

SIGNATURE REQUIRED BELOW TO PROCEED WITH TESTING.

MY SIGNATURE INDICATES I ACCEPT FINANCIAL RESPONSIBILITY FOR ALL FEES ASSOCIATED WITH THIS GENETIC TESTING ORDER. If applicable, I authorize PreventionGenetics to release information received including, without limitation, medical information, which includes laboratory test results, such as genetic tests results, to my health plan / insurance carrier and its Authorized Representatives. I further authorize insurance payments directly to PreventionGenetics for the services rendered. I understand my Health Plan / Insurance / Medicare / Medicaid carrier may not approve and reimburse my medical genetic services in full due to usual and customary rate limits, benefit exclusions, coverage limits, lack of authorization, medical necessity or otherwise. **I understand I am financially responsible for fees not paid in full by my insurer**, co-payments, and policy deductibles except where my liability is limited by contract or State and Federal law. I agree to help PreventionGenetics resolve any insurance claim issues. I understand my out-of-network benefits may apply. PreventionGenetics may contact me to resolve any billing-related issues and to request payment.

SIGN HERE:
Required to process form

PATIENT / RESPONSIBLE PARTY SIGNATURE

PRINTED NAME OF RESPONSIBLE PARTY

DATE

CREDIT CARD PAYMENT

• PATIENT PROMPT PAY (excludes insurance billing)

Card information provided below will be charged when specimen arrives. The 10% Patient Prompt Pay discount will apply.

• PATIENT PAY - INSURANCE BILLING

Card information provided below will be charged when the claim is processed. The 10% Patient Prompt Pay discount **WILL NOT** apply.

CREDIT CARD INFORMATION

CREDIT CARD NUMBER (VISA, DISCOVER, OR MASTERCARD ONLY)

EXPIRATION DATE

3-DIGIT SECURITY CODE

My signature authorizes PreventionGenetics to charge my credit card for services for which I am responsible.

SIGN HERE:
Required to process credit card

CREDIT CARD HOLDERS SIGNATURE

DATE

INSURANCE INFORMATION - IF APPLICABLE

INDICATE THE TYPE OF INSURANCE ☐ Attach a copy of Insurance Card (both sides)

☐ PRIVATE

☐ TRICARE include signed Tricare waiver

☐ MEDICARE include signed ABN form

☐ MEDICAID

Visit PreventionGenetics.com for in-network Medicaid plans.

POLICY HOLDER NAME

DATE OF BIRTH (MM/DD/YYYY)

RELATIONSHIP TO PATIENT

PRIMARY INSURANCE COMPANY NAME (REQUIRED)

PHONE NUMBER

POLICY ID#

GROUP #

AUTHORIZATION #

☐ Attach copy of authorization, PreventionGenetics must be listed as servicing provider.

SECONDARY INSURANCE ☐ Attach a copy of Insurance Card (both sides)

TESTING WILL PROCEED UNLESS:

- We (or you) are working on a required Pre-Authorization.
- No insurance coverage is available. We will work with you or your patient to determine payment options.

OR PLEASE PROVIDE YOUR PREFERENCES BELOW:

☐ **HOLD TESTING** for benefit investigation / pre-authorization and share results with patient directly via email provided.

☐ **PROCEED WITH TESTING:** patient accepts financial responsibility for test; regardless of insurance coverage.

(All tests with an in-network insurance are held for benefits investigation, regardless of selected option, except for prenatal and Rapid NICU tests.)

☐ **OTHER:** _____

NOTE: Prenatal CMA, re-analysis, and cell cultures cannot be canceled once a sample is received. Testing placed on hold will extend overall TAT.

PGxome® Whole Exome Sequencing

HEALTHCARE PROVIDERS STATEMENT

This statement is required for patient specimens collected in NY and recommended for others, and applies to Whole Exome Sequencing.

PATIENT INFORMATION

LAST (FAMILY) NAME	FIRST NAME	MI	DATE OF BIRTH (MM/DD/YYYY)

FAMILY MEMBERS

If a Family (duo, trio, etc.) is being tested, please provide family member information:

FAMILY MEMBER'S NAME	RELATIONSHIP
FAMILY MEMBER'S NAME	RELATIONSHIP
FAMILY MEMBER'S NAME	RELATIONSHIP

I have provided informed consent to my patient. My patient has had the opportunity to ask questions. Please indicate patient preferences for secondary findings on the PGxome® Test Requisition Form.

HEALTHCARE PROVIDER SIGNATURE

PRINTED NAME

DATE

Retention of Unused DNA Statement for New York State Specimens

PreventionGenetics' general policy is to retain all excess DNA from patient testing indefinitely. This allows for easier ordering of additional testing in the future and saves considerable phlebotomy and shipping costs to the patient and healthcare system. Excess DNA specimens can also be used for quality control measures or for research on genetic variants associated with the diseases or conditions I was tested for, and any related diseases or conditions, which may include further testing of my retained samples, subject to approval by an Institutional Review Board or as otherwise permitted under applicable law. New York (NY) law requires patient consent in order to retain excess DNA beyond 60 days. If patient specimen was collected in NY and this statement is not signed, excess DNA will be discarded 30 days after testing is completed.

I authorize PreventionGenetics to retain unused DNA for potential future testing ordered by my Healthcare Provider and for the purposes described above.

PATIENT OR LEGAL REPRESENTATIVE SIGNATURE

PRINTED NAME

DATE

The following information should be used as a guide to provide informed consent to the patient and/or patient's family. Testing must be ordered by a qualified Healthcare Provider.

PURPOSE

- **Diagnostic PGxome:** The purpose of this test is to find the underlying genetic cause for the patient's health condition using Whole Exome Sequencing (WES).
- **Health Screen PGxome:** The purpose of this test is to provide pan-ethnic carrier screening using a Whole Exome Sequencing (WES) test. Variants in any gene that relate to an autosomal recessive or X-linked recessive disorder (in females) would be reported (regardless of the incidence of the condition). In addition, patients have the option of also receiving genetic variants that predispose to autosomal or X-linked dominant disorders or X-linked recessive disorders (in males).

ABOUT PGXOME TEST

- This test involves the sequencing of thousands of genes at the same time, whereas many other genetic tests look at only one gene or a small group of genes. The way we

perform the exome test is through a procedure called Next Generation Sequencing (NGS). We confirm important results with another type of sequencing called Sanger sequencing. Copy number variants (CNVs), also known as deletions/duplications, and are detected from NGS data. All reported CNVs are confirmed using another technology such as aCGH, MLPA, or PCR.

- We will need about one teaspoon of blood (3-5 ml of whole blood or DNA extracted from blood) from each individual to perform testing. In rare instances, a second specimen may be requested.
- Results of the test will be presented in an individualized, written report transmitted to the patient's Healthcare Provider(s).
- For additional information about this test, see the Diagnostic PGxome test description on the PreventionGenetics website.

FAMILY TESTING (Diagnostic PGxome Only)

- Testing of family members is very helpful for interpretation of results. When possible, testing of the patient and two

other family members (called a trio), preferably biological parents, should be performed. If one or both biological parents are unavailable, sometimes siblings or other close relatives can be tested. Family testing increases the chance of getting a conclusive result.

- It is very important family genetic relationships are correctly stated because issues such as an undisclosed adoption or uncertain paternity can cause confusion. If you are aware of any such issues in the family, they should be discussed confidentially with your Genetic Counselor or Ordering Physician.
- Family member information (i.e. parental genotype information) helps us interpret the patient's results and will be included in the patient's report. All sequence variants reported will include parental status. While large CNVs identified in the proband may include parental inheritance information, confirmation using an additional method will not be performed on parental specimens. If parental status for variants in the patient's report is not desired (for primary and/or secondary findings), please make note of this under "Patient Test Selection".

Family members tested as part of a Family PGxome can request their own full analysis reports for an additional charge. Appropriate separate orders (Pgxome Diagnostic or PG Health Screen) are required.

REPORT INFORMATION

Diagnostic PGxome:

- Genetic variants are defined as the differences between the patient's DNA and the human reference DNA. Generally only results that may explain the patient's clinical features will be reported.
- In genes believed to be associated or possibly associated with the patient's clinical features, all Pathogenic, Likely Pathogenic, and Variants of Uncertain Significance (unknown if they cause disease) will be reported.

Health Screen PGxome:

- Pathogenic and Likely Pathogenic recessive sequence variants (Richards et al. 2015 Genet Med 17:405-424) within genes currently known to be clinically relevant for carrier status in autosomal recessive disorders or X-linked recessive disorders (in females) will be reported. Variants in genes not currently known to be clinically relevant will not be reported.
- Some individuals may have two Pathogenic or Likely Pathogenic genetic variants (compound heterozygous or homozygous) in a gene that causes an autosomal recessive disorder. Even if the patient may not be obviously affected by the disorder, this finding could lead to a diagnosis. If identified this information will be included in the patient's test report as it also indicates a positive carrier status.
- The patient will very likely have many recessive Variants of Uncertain Significance. These variants will not be included in the report, but the laboratory will retain this data.

Other findings (aka "Secondary Findings" - see below) may be reported depending on the patient's preferences (see bottom of first page of Test Requisition Form). These Secondary Findings may have an important impact on health.

New research results are continually improving the ability to interpret the WES results. An ordering Healthcare Provider can request a re-interpretation from us.

ISSUING THE REPORT

- Results will be sent directly to the ordering Healthcare Provider(s) and NOT to the patient.
- Genetic counseling and/or clinical genetics consultation before and after testing is recommended.
- Patients have the right to receive a copy of their test report. They may obtain a copy from their Healthcare Provider(s) or if a signed patient authorization (form available upon request) is received, from PreventionGenetics.

SECONDARY FINDINGS

In many patients, WES will reveal one or more additional genetic variants which could be important to the patient's health. These include for example variants predisposing the patient to cancer or heart disease, or variants relevant to reproductive planning. These are termed secondary findings. The patient may or may not wish to be informed of secondary findings.

- Secondary findings are not available for Rapid PGxome.
- Carrier Status is always reported for Health Screen PGxome. The patient will have a choice about what other secondary findings are reported.
- For Standard Diagnostic PGxome the patient and/or patient's family will have a choice on which types of secondary findings are reported.

Please consider the following carefully. Variants described in these sections will only be reported if the patient OPTS IN.

SECONDARY FINDINGS NO CHARGE OPT INS

- Guideline Recommended Genes:** The American College of Medical Genetics and Genomics recommends all labs performing WES report pathogenic variants in specific genes that cause certain, mostly dominantly inherited disorders (Version 3.3, Lee et al. 2025, PubMed ID 40568962). These disorders are treatable and/or preventable. Included on this list are some cancer predisposition conditions, heart conditions associated with sudden

death, and conditions that could result in severe health consequences if surgery is performed with certain anesthetics.

- PG Discovery (Candidate Genes, Available for Diagnostic PGxome Trios with Biological Parents Only):** WES provides the opportunity to identify rare variants in candidate genes for which there is limited available evidence. Relevant rare homozygous, hemizygous, compound heterozygous, and/or *de novo* variants are reported. These genes and variants reported within them will be classified as uncertain significance, and the variants will not be confirmed by a second method. Any literature, such as limited animal studies, etc., is referenced where available. Further research is required to understand if any human disease association exists. PreventionGenetics may reach out to request consent for submission of these variants to research programs and databases like GeneMatcher (<https://genematcher.org/>).

ADD ON SECONDARY FINDINGS

(additional charge)

Please consider the following carefully. Variants described in these sections will only be reported if the patient OPTS IN (additional charges will apply).

- Other Predispositions/Diagnoses:** This secondary finding option refers to a very broad range of disorders beyond the Guideline Recommended Genes above. Examples vary widely and include adult onset neurological conditions such as Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis (ALS), and small vessel disease, as well as cancer predispositions, and renal conditions, among others. Some of these disorders are very serious, leading to death. While treatment or prevention will be effective for some of these disorders but not others, knowledge of these predispositions may be useful for the patient and their family. (Amendola et al. 2015. Genome Res 25(3):305-315; Dorschner et al. 2013. Am J Hum Genet 93(4):631-640). Some people may want to know about these disorders while others may prefer not to know. If this option is selected, all pathogenic and likely pathogenic variants in genes that are likely to result in a Mendelian (single gene) disorder (i.e., one variant in a dominant gene or X-linked gene or two variants in a recessive gene) will be reported.

Many of these conditions have adult onset, reviewing professional guidelines before discussing these options with minors and their families is recommended (Borry et al. 2006 Clin Genet 70(5):374-81; Lucassen et al. 2010 British Society for Human Genetics; Fallat et al. 2013 Pediatrics 131(3): 620-2; NSGC Position Statement 2017). For minors, predictive testing should be postponed until they have reached an age capable of true informed consent (ability to understand the risks, benefits, and implications of results). Consideration of testing in minors should ideally include genetic counseling, the parents, and assent of the child.

- Carrier Status (included n/c in Health Screen orders):** WES can also provide panethnic carrier screening. For carrier status, variants in any gene that relate to an autosomal recessive or X-linked recessive disorder (in females) would be reported if this option is selected (regardless of the incidence of the condition). Such single recessive, pathogenic variants usually don't appreciably affect a patient's health, but may be useful in reproductive planning. In accordance with current professional guidelines, we do not recommend release of carrier information to minors (under the age of 18 years). For minors, carrier testing should be postponed until they have reached an age capable of true informed consent (ability to understand the risks, benefits, and implications of results). Consideration of testing in minors should ideally include genetic counseling, the parents, and assent of the child. (Borry et al. 2006. Eur J Hum Genet 14(2):133-8; NSGC Position Statement 2012; Ross et al. 2013 Genet Med 15(3):234-245). For minors, predictive testing should be postponed until they have reached an age capable of true informed consent (ability to understand the risks, benefits, and implications of results). Consideration of testing in minors should ideally include genetic counseling, the parents, and assent of the child.

Genetic variants related to complex disease, and mitochondrial disorders (excluding nuclear genes) will not be reported at this time.

Genetic variants in genes not currently known to be clinically relevant will not be reported unless trio testing is ordered and PG Discovery is selected.

If testing reveals the family relationships are not as expected (for example, non-paternity), this information will be relayed to the healthcare provider(s) for discussion, but will not be included in the patient's report.

DATA

PreventionGenetics will store the patient's sequence data. This will permit reanalysis and reinterpretation of the data in the future. Upon a physician's request, PreventionGenetics will perform, without additional charge, one reanalysis and reinterpretation of the data within three years of the date on the original test report. Thereafter, reanalysis and reinterpretation may be requested, but a fee will be charged for this service.

PreventionGenetics recommends DNA sequence information from this test be stored in the patient's electronic medical record. This will best benefit the patient and family members. PreventionGenetics will provide WES data to an ordering provider upon request. PreventionGenetics does not supply software for data review and interpretation.

RISKS

Blood draw risks include bruising and bleeding. There is also a small chance the patient may get an infection, have excess bleeding, become dizzy, or faint from the blood draw.

Learning about test results can be stressful and upsetting.

The patient and/or patient's family may have concerns about genetic discrimination, including health insurance, life insurance, employment and long-term disability. These should be addressed according to federal and state laws. The Federal Genetic Information Non-discrimination Act (GINA) prohibits the use of genetic information for discrimination in health insurance and employment.

LIMITATIONS

This test targets most, but not all, of the coding parts of our genes (called exons). All of the exons together is called the exome. The exome only covers approximately 1.5% of all the genetic material. However, testing the exome covers the vast majority of genetic variants which cause single gene (or Mendelian) disorders.

Interpretation of the test results is limited by the information currently available. Better interpretation could be possible in the future as more data and knowledge about human genetics are accumulated.

Testing will detect single base pair changes and small and large deletions or duplications, but is generally unable to detect other types of genetic changes (e.g. rearrangements, inversions, deep intronic variants, methylation abnormalities, or repetitive sequence changes).

This test will not provide detection of certain genes or specific exons of genes due to complicated technicalities (such as sequence characteristics, interfering pseudogenes, or inadequate coverage). In the case of deletions/duplications, most will be detected including intragenic CNVs and large cytogenetic events. CNVs of 4 exons or more in size are detected with sensitivity approaching 100% through analysis of NGS data. However, sensitivity for detection of CNVs smaller than 4 exons is lower (the estimate ~75%). Sensitivity may vary from gene-to-gene based on exon size, depth of coverage, and characteristics of the region. Because of these technicalities, this test is not 100% sensitive and will not identify all disease-causing genetic variants.

Even if a disease-causing genetic variant associated with the patient's symptoms is identified, it may not allow for predictions regarding severity of the disease or prognosis.

It is very important your Healthcare Provider(s) provide an accurate family history and clinical information as that information is critical for result interpretation. Detailed clinical information (such as clinical features, a family pedigree, and results of prior testing) is required for testing to proceed.

Additional limitations to this test will be provided in the Supplementary material included with the test report.

CONFIDENTIALITY

Confidentiality and patient privacy are taken very seriously. The laboratory is CAP and CLIA certified, and adheres to confidentiality laws related to protected health information.

CLINICAL INFORMATION IS REQUIRED for PGnome®, PGxome®, and PGmax™ panels.

Orders **MUST** include the completed clinical features checklist (preferred) or clinical notes/records. Completion of the checklist is strongly encouraged for all panel testing. The ability to interpret variants directly correlates with the quality of clinical information provided. Also include family medical history/pedigree, if available.

CLINICAL INFORMATION (CHECK ALL THAT APPLY)

PRE/PERINATAL

- ☐ Abnormality of septum pellucidum
 - ☐ Absent septum pellucidum
 - ☐ Cavum septum pellucidum
- ☐ Choroid plexus cyst (CPC)
- ☐ Absent nasal bone
- ☐ Congenital heart defect
- ☐ Intracardiac echogenic focus (IEF)
- ☐ Cystic hygroma
- ☐ Increased nuchal translucency, Size (mm): _____
- ☐ Pleural effusion
- ☐ Pericardial effusion
- ☐ Generalized edema
- ☐ Fetal ascites
- ☐ Hydrops fetalis
- ☐ Diaphragmatic hernia
- ☐ Absent stomach bubble
- ☐ Omphalocele
- ☐ Gastroschisis
- ☐ Echogenic bowel
- ☐ Fetal pyelectasis/hydronephrosis
- ☐ Decreased fetal movement
- ☐ Encephalocele
- ☐ Myelomeningocele/Spina bifida
- ☐ Sacrococcygeal teratoma
- ☐ Intrauterine growth retardation (IUGR)
- ☐ Small for gestational age (SGA)
- ☐ Oligohydramnios
- ☐ Polyhydramnios
- ☐ Short long bones
- ☐ Small thorax
- ☐ Fetal demise
- ☐ Prematurity, Gestational Age: _____
- ☐ Other: _____

STRUCTURAL BRAIN ABNORMALITIES / IMAGING

- ☐ Abnormal/delayed myelination
- ☐ Abnormality of basal ganglia
- ☐ Abnormality of brainstem
- ☐ Abnormality of white matter:
 - ☐ Periventricular
 - ☐ Other: _____
- ☐ Abnormality of cerebral ventricles:
 - ☐ Colpocephaly
 - ☐ Hydrocephalus
 - ☐ Ventriculomegaly
- ☐ Abnormality of corpus callosum morphology:
 - ☐ Agenesis
 - ☐ Complete
 - ☐ Partial
 - ☐ Aplasia/hypoplasia

- ☐ Aplasia/hypoplasia of cerebellar vermis
- ☐ Aplasia/hypoplasia of cerebellum
- ☐ Arnold-Chiari malformation:
 - ☐ Type I
- ☐ Cerebral atrophy/hypoplasia
- ☐ Cerebral calcification
- ☐ Holoprosencephaly
- ☐ Intraventricular hemorrhage
 - ☐ Preterm Intraventricular hemorrhage
- ☐ Iron deposition
- ☐ Leukodystrophy
- ☐ Neuronal migration abnormality
 - ☐ Cortical gyration
 - ☐ Gray matter heterotopia
- ☐ Other: _____

DEVELOPMENTAL/ BEHAVIORAL

- ☐ Aggressive/violent behavior
- ☐ Anxiety
- ☐ Attention-deficit hyperactivity disorder
- ☐ Autistic behavior
- ☐ Autism/autism spectrum disorder
- ☐ Cognitive impairment
- ☐ Delayed fine motor development
- ☐ Delayed gross motor development
- ☐ Developmental regression
- ☐ Gait disturbance
 - ☐ Specify: _____
- ☐ Global developmental delay
- ☐ Hyperactivity
- ☐ Incoordination
- ☐ Intellectual disability
 - ☐ Mild
 - ☐ Moderate
 - ☐ Severe/profound
- ☐ Learning disability
- ☐ Language impairment
 - ☐ Absent speech
 - ☐ Apraxia
 - ☐ Articulation difficulties
 - ☐ Delayed speech and language development
 - ☐ Expressive
 - ☐ Receptive
 - ☐ Dysarthria
 - ☐ Echolalia
 - ☐ Loss of speech
- ☐ Memory impairment
- ☐ Obsessive-compulsive behavior
- ☐ Self-injurious behavior:
 - ☐ Biting
 - ☐ Head-banging
 - ☐ Skin picking

- ☐ Sensory processing disorder/ neurodevelopmental abnormality
- ☐ Sleep disturbance
- ☐ Stereotypy
 - ☐ Recurrent hand flapping
 - ☐ Stereotypical hand wringing
- ☐ Other: _____

NEUROLOGICAL

- ☐ Abnormality of nervous system
- ☐ Ataxia
- ☐ Athetosis
- ☐ Bradykinesia
- ☐ Cerebral palsy
- ☐ Chorea
- ☐ Cortical visual impairment
- ☐ Dementia
- ☐ Dysarthria
- ☐ Dyskinesia
- ☐ Dysphagia
- ☐ Dystonia
- ☐ Encephalopathy
- ☐ Gait disturbance, Specify: _____
- ☐ Headache
- ☐ Hemiplegia
- ☐ Hypotonia
- ☐ Hypertonia
- ☐ Infantile spasms
- ☐ Migraine
- ☐ Myoclonus
- ☐ Neuropathy
 - ☐ Peripheral
 - ☐ Sensory
- ☐ Parkinsonism/Parkinson Disease
- ☐ Seizures, Type: _____
- ☐ Spasticity
- ☐ Syncope
- ☐ Tremors
- ☐ Vertigo
- ☐ Other: _____

CRANIOFACIAL/ DYSMORPHISM

- ☐ Abnormal facial shape, Specify: _____
- ☐ Abnormality of incisors, Specify: _____
- ☐ Ala nasi
 - ☐ Cleft
 - ☐ Thick
 - ☐ Underdeveloped
- ☐ Anteverted nares
- ☐ Brachycephaly
- ☐ Chin abnormality, Specify: _____

- ☐ Cleft lip:
 - ☐ Unilateral
 - ☐ Bilateral
 - ☐ Midline
- ☐ Cleft palate:
 - ☐ Unilateral
 - ☐ Bilateral
 - ☐ Midline
 - ☐ Submucous cleft
- ☐ Cloverleaf skull
- ☐ Columella abnormality:
 - ☐ Broad
 - ☐ High insertion
 - ☐ Low hanging
 - ☐ Low insertion
 - ☐ Short
- ☐ Craniosynostosis:
 - ☐ Coronal
 - ☐ Lambdoidal
 - ☐ Metopic
 - ☐ Orbital
 - ☐ Sagittal
- ☐ Dolichocephaly
- ☐ Face abnormality:
 - ☐ Broad
 - ☐ Coarse facial features
 - ☐ Flat
 - ☐ Long
 - ☐ Narrow
 - ☐ Round
 - ☐ Short
 - ☐ Square
 - ☐ Triangular
- ☐ Forehead abnormality:
 - ☐ Broad
 - ☐ Narrow
 - ☐ Prominent
 - ☐ Sloping
 - ☐ Creases
- ☐ Frontal bossing
- ☐ Jaw abnormality:
 - ☐ Broad
 - ☐ Narrow
- ☐ Lip vermilion abnormality
- ☐ Lip abnormality:
 - ☐ Pit
 - ☐ Thin
 - ☐ Thick
 - ☐ Tentid
 - ☐ Exaggerated cupid's bow
 - ☐ Absent cupid's bow
- ☐ Malar abnormality:
 - ☐ Flattening
 - ☐ Prominence
- ☐ Midface abnormality:
 - ☐ Flat
 - ☐ Prominence
 - ☐ Retrusion

If additional space is required for an other description or "specify" line, please continue your response on the open text box of page 4. Include a continued notation from on the other or specify line

- ☐ Macrocephaly:
☐ Relative
☐ True
- ☐ Metopic suture abnormality:
☐ Depression
☐ Ridge
- ☐ Microcephaly
- ☐ Micrognathia
- ☐ Nasal base abnormality:
☐ Narrow
☐ Wide
- ☐ Nasal bridge abnormality:
☐ Depressed
☐ Narrow
☐ Prominent
☐ Short
☐ Wide
- ☐ Nasal cartilage, absent
- ☐ Nasal ridge abnormality:
☐ Depressed
☐ Narrow
☐ Wide
- ☐ Nasal tip abnormality:
☐ Bifid
☐ Broad
☐ Depressed
☐ Deviated
☐ Narrow
☐ Overhanging
- ☐ Nasolabial fold abnormality:
☐ Prominent
☐ Underdeveloped
- ☐ Neck abnormality:
☐ Broad
☐ Long
☐ Webbed
☐ Short
☐ Redundant nuchal skin
- ☐ Nose abnormality:
☐ Absent
☐ Bifid
☐ Long
☐ Narrow
☐ Prominent
☐ Short
☐ Wide
- ☐ Occiput abnormality:
☐ Flat
☐ Prominent
- ☐ Plagiocephaly
- ☐ Philtrum abnormality:
☐ Broad
☐ Deep
☐ Hypoplastic
☐ Long
☐ Narrow
☐ Smooth
☐ Short
☐ Tented
- ☐ Proboscis
- ☐ Prognathism
- ☐ Retrognathia
- ☐ Scaphocephaly
- ☐ Supraorbital ridge abnormality:
☐ Prominent
☐ Underdeveloped
- ☐ Trionocephaly

- ☐ Turricephaly
- ☐ Other: _____
- EYES/VISION**
- Age of onset of vision issues: _____
- ☐ Abnormality of eye movement
☐ Esotropia
☐ Exotropia
☐ Nystagmus
☐ Smooth pursuit
☐ Strabismus
☐ Other: _____
- Abnormality of vision,
Specify: _____
- ☐ Abnormal anterior eye segment morphology
- ☐ Ablepharon
- ☐ Achromatopsia
- ☐ Aniridia
- ☐ Ankyloblepharon
- ☐ Anophthalmia
- ☐ Blepharochalasis
- ☐ Blepharophimosis
- ☐ Cataracts
- ☐ Cataracts, congenital
- ☐ Coloboma
- ☐ Corneal opacity
- ☐ Corneal dystrophy
- ☐ Cone/cone-rod dystrophy
- ☐ Congenital stationary night blindness
- ☐ Cryptophthalmos
- ☐ Deeply set eyes
- ☐ Distichiasis
- ☐ Dyschromatopsia (color blindness)
- ☐ Ectopia lentis
- ☐ Ectropion
- ☐ Entropion
- ☐ Epiblepharon
- ☐ Epicanthus/epicanthal folds
- ☐ Epicanthus inversus
- ☐ Eyebrow abnormality:
☐ Broad
☐ Highly arched
☐ Horizontal
☐ Sparse
☐ Thick
- ☐ Eyelash abnormality:
☐ Absent
☐ Long
☐ Prominent
☐ Sparse
- ☐ Eyelid cleft
- ☐ External ophthalmoplegia
☐ Progressive
- ☐ Glaucoma
- ☐ Infraorbital abnormality:
☐ Crease
☐ Fold
- ☐ Iris abnormality,
Specify: _____
- ☐ Lagophthalmos
- ☐ Leber optic atrophy

- ☐ Lens subluxation
- ☐ Macular abnormality,
Specify: _____
- ☐ Macular dystrophy
- ☐ Microphthalmia
- ☐ Myopia
- ☐ Ocular albinism
- ☐ Optic atrophy
- ☐ Optic neuropathy
- ☐ Palpebral fissure abnormality:
☐ Downslanted
☐ Upslanted
☐ Long
☐ Short
☐ Almond-shaped
- ☐ Ptosis
- ☐ Retinal flecks
- ☐ Retinal detachment
- ☐ Retinitis pigmentosa
- ☐ Synophrys
- ☐ Telecanthus
- ☐ Other: _____
- EARS/HEARING**
- Age of onset of hearing loss: _____
- ☐ Hearing impairment
☐ Sensorineural
☐ Congenital
☐ Bilateral
☐ Progressive
☐ Conductive
☐ Congenital
☐ Bilateral
☐ Progressive
☐ Mixed
- ☐ Anotia
- ☐ Abnormal newborn screen,
Specify: _____
- ☐ Antihelix abnormality:
☐ Absent
☐ Additional crus
☐ Angulated
☐ Inferior crus broad
☐ Inferior crus prominent
☐ Inferior crus underdeveloped
☐ Superior crus prominent
☐ Superior crus underdeveloped
- ☐ Antitragus abnormality:
☐ Absent
☐ Bifid
☐ Everted
☐ Prominent
☐ Underdeveloped
- ☐ Ear abnormality:
☐ Abnormality of the tragus
☐ Auricular pit
☐ Crumpled
☐ Cupped
☐ Long
☐ Low-set
☐ Posteriorly rotated
☐ Preauricular pit
☐ Protruding
☐ Short
☐ Satyr
☐ Tag

- ☐ Helix abnormality:
☐ Cleft / Notching
☐ Crimped
☐ Darwin notch
☐ Darwin tubercle
☐ Notching
☐ Overfolded
☐ Prominent
☐ Thin
- ☐ Lobe abnormality:
☐ Cleft
☐ Forward-facing
☐ Large
☐ Small
☐ Uplifted
- ☐ Macrotia
- ☐ Other: _____
- ENDOCRINE**
- ☐ Adrenal insufficiency (Addison)
- ☐ Androgen excess
- ☐ Androgen insensitivity
- ☐ Congenital adrenal hypoplasia
- ☐ Congenital adrenal hyperplasia
- ☐ Delayed bone age
- ☐ Delayed puberty
- ☐ Diabetes insipidus
- ☐ Diabetes Mellitus
- ☐ Hyperandrogenism
- ☐ Hyperglycemia
- ☐ Hyperphosphatemia
- ☐ Hyperthyroidism
- ☐ Hypoglycemia
- ☐ Hypophosphatemia
- ☐ Hypothyroidism
- ☐ Increased cortisol level (Cushing)
- ☐ Maturity-onset diabetes of the young
- ☐ Precocious puberty
- ☐ Rickets
- ☐ Other: _____
- RESPIRATORY**
- ☐ Asthma
- ☐ Bronchiectasis
- ☐ Bronchomalacia
- ☐ Hyperventilation
- ☐ Hypoventilation
- ☐ Laryngomalacia
- ☐ Laryngeal cleft
- ☐ Pneumothorax
- ☐ Pulmonary fibrosis
- ☐ Respiratory insufficiency
- ☐ Tracheomalacia
- ☐ Tracheoesophageal fistula
- ☐ Other: _____
- HEMATOLOGIC/IMMUNOLOGIC**
- ☐ Agammaglobulinemia
- ☐ Allergic rhinitis
- ☐ Anemia
- ☐ Hemolytic anemia
- ☐ Immunodeficiency,
Specify: _____
- ☐ Lymphopenia

- ☐ Neutropenia
- ☐ Pancytopenia
- ☐ Recurrent infections
- ☐ Severe combined immunodeficiency
- ☐ Thrombocytopenia
- ☐ Other: _____

SKIN/HAIR

- ☐ Abnormal blistering of the skin, Specify: _____
- ☐ Abnormality of nail:
 - ☐ Broad
 - ☐ Deep-set
 - ☐ Pits
- ☐ Albinism
- ☐ Alopecia
- ☐ Anhidrosis
- ☐ Cafe-au-lait spot:
 - ☐ Single
 - ☐ Multiple
- ☐ Coarse hair
- ☐ Collodion baby
- ☐ Cutaneous photosensitivity
- ☐ Cutis laxa
- ☐ Dry skin
- ☐ Eczema
- ☐ Erythematous skin
- ☐ Hemangioma
- ☐ Hairline:
 - ☐ Anterior
 - ☐ Low
 - ☐ High
 - ☐ Posterior
 - ☐ Low
 - ☐ High
- ☐ Hyperextensible skin
- ☐ Hyperpigmentation of the skin
- ☐ Hypopigmentation of the skin
- ☐ Hypohidrosis
- ☐ Ichthyosis
- ☐ Jaundice
- ☐ Lipoma
- ☐ Lymphedema
- ☐ Palmoplantar keratoderma
- ☐ Scarring of skin
- ☐ Skin rash
- ☐ Sparse hair
- ☐ Telangiectasia
- ☐ Vascular skin abnormality
- ☐ Velvety skin
- ☐ Other: _____

CARDIAC

- ☐ Amyloidosis
- ☐ Aortic root dilatation
- ☐ Arrhythmia
- ☐ Atrial septal defect
- ☐ Atrioventricular canal defect
- ☐ Arrhythmogenic right ventricular dysplasia
- ☐ Bicuspid aortic valve
- ☐ Bradycardia

- ☐ Coarctation of the aorta
- ☐ Congenital heart defect
- ☐ Dilated cardiomyopathy
- ☐ Double outlet right ventricle
- ☐ Ebstein anomaly
- ☐ Heterotaxy
- ☐ Hypertension
- ☐ Hypertrophic cardiomyopathy
- ☐ Mitral valve prolapse
- ☐ Noncompaction cardiomyopathy
- ☐ Patent ductus arteriosus
- ☐ Patent foramen ovale
- ☐ Prolonged QTc interval
- ☐ Pulmonary hypertension
 - ☐ Arteria
 - ☐ Vascular
- ☐ Sudden death
- ☐ Tetralogy of Fallot
- ☐ Transposition of the great vessels
- ☐ Truncus arteriosus
- ☐ Ventricular septal defect
- ☐ Ventricular tachycardia
- ☐ Other: _____

GASTROINTESTINAL

- ☐ Biliary atresia
- ☐ Cholestasis
- ☐ Constipation:
 - ☐ Acute
 - ☐ Chronic
- ☐ Diarrhea
- ☐ Diaphragmatic hernia
- ☐ Duodenal stenosis/atresia
- ☐ Esophageal stenosis/atresia
- ☐ Exocrine pancreatic insufficiency
- ☐ Failure to thrive
- ☐ Feeding difficulties
- ☐ Gastroesophageal reflux
- ☐ Gastroschisis
- ☐ Hepatomegaly
- ☐ Hepatosplenomegaly
- ☐ Inflammatory bowel disease
- ☐ Jaundice
- ☐ Liver disease
- ☐ Liver failure
- ☐ Nausea
- ☐ Omphalecele
- ☐ Pancreatitis
- ☐ Pyloric stenosis
- ☐ Splenomegaly
- ☐ Tracheoesophageal fistula
- ☐ Tube feeding
 - ☐ Nasogastric
 - ☐ Gastrostomy
 - ☐ Gastrojejun
- ☐ Umbilical hernia
- ☐ Vomiting
- ☐ Other: _____

GENITOURINARY

- ☐ Abnormality of the uterus, Specify: _____

- ☐ Ambiguous genitalia
- ☐ Chordee
- ☐ Cryptorchidism
- ☐ Duplicated collecting system
- ☐ Horseshoe kidney
- ☐ Hydronephrosis
- ☐ Hypospadias/epispadias
- ☐ Inguinal hernia
- ☐ Micropenis
- ☐ Multicystic kidney dysplasia
- ☐ Nephrolithiasis
- ☐ Polycystic kidney disease
- ☐ Renal agenesis/hypoplasia
 - ☐ Unilateral agnensis
 - ☐ Bilateral agnensis
 - ☐ Unilateral hypoplasia
 - ☐ Blateral hypoplasia
- ☐ Sex reversal
- ☐ Vesicoureteral reflux
- ☐ Other: _____

MUSCULOSKELETAL

- ☐ Abnormal connective tissue
- ☐ Abnormal digit morphology
 - ☐ Broad
 - ☐ Short
 - ☐ Clinodactyly
 - ☐ Ectrodactyly
 - ☐ Oligodactyly
 - ☐ Polydactyly
 - ☐ Postaxial
 - ☐ Preaxial
 - ☐ Syndactyly
- ☐ Arachnodactyly
- ☐ Arthralgia
- ☐ Arthrogryposis
- ☐ Bruising susceptibility
- ☐ Chest abnormality:
 - ☐ Small chest
 - ☐ Barrel-shaped
 - ☐ Bell-shaped thorax
 - ☐ Pectus carinatum
 - ☐ Pectus excavatum
- ☐ Contractures of joint(s)
- ☐ Decreased muscle mass
- ☐ Delayed bone age
- ☐ Dolichostenomelia
- ☐ Exercise intolerance
- ☐ Fatigue
- ☐ Fracture(s)
- ☐ Hemihypertrophy
- ☐ Hypertonia
- ☐ Hypotonia
- ☐ Joint hypermobility
- ☐ Kyphosis
- ☐ Limb shortening:
 - ☐ Mesomelic
 - ☐ Micromelic
 - ☐ Rhizomelic
- ☐ Metaphyseal abnormalities:
 - ☐ Dumbbell
 - ☐ Flared
- ☐ Muscle weakness
- ☐ Myalgia

- ☐ Myopathic facies
- ☐ Myopathy
- ☐ Myelomeningocele/Spina Bifida/Neural Tube Defect
- ☐ Osteoarthritis
- ☐ Osteoporosis
- ☐ Osteopenia
- ☐ Pain:
 - ☐ Absent/decreased
 - ☐ Abnormal sensation
 - ☐ Episodic
 - ☐ Limb
 - ☐ Muscle
- ☐ Platyspondyly
- ☐ Recurrent fractures
- ☐ Rhabdomyolysis
- ☐ Rib abnormality:
 - ☐ Cupped
 - ☐ Fused
 - ☐ Supernumerary
 - ☐ Missing
 - ☐ Short
 - ☐ Spatulate
 - ☐ Other: _____
- ☐ Rickets
- ☐ Scoliosis
- ☐ Short stature
- ☐ Skeletal dysplasia
- ☐ Talipes
 - ☐ Equinovarus
 - ☐ Other: _____
- ☐ Tall stature
- ☐ Thoracic dysplasia
- ☐ Thumb abnormality:
 - ☐ Adducted
 - ☐ Broad
 - ☐ Triphalangeal
- ☐ Vertebral bodies, abnormal form
 - ☐ Aplasia/hypoplasia
 - ☐ Butterfly
 - ☐ Fusion
 - ☐ Hemivertebrae
- ☐ Other: _____

VASCULAR SYSTEM

- ☐ Aneurysm
- ☐ Aortic:
 - ☐ Abdominal
 - ☐ Dissecting
 - ☐ Thoracic
- ☐ Cerebral
 - ☐ Other: _____
- ☐ Arterial calcification
- ☐ Arterial dissection
- ☐ Arterial tortuosity
- ☐ Arteriovenous malformation
- ☐ Epistaxis
- ☐ Lymphedema
- ☐ Pulmonary hypertension:
 - ☐ Arterial
 - ☐ Vascular
- ☐ Stroke
- ☐ Other: _____

PATIENT	
LAST NAME	
FIRST NAME	MI

OTHER TESTING Provide copy of report(s)

Echocardiogram: _____
 EEG: _____
 EMG/NCV: _____
 Biopsy: _____
 Gene testing: _____
 Results: _____

If you would like us to comment on the presence/absence of previously identified variants, provide a copy of the original report.

Chromosomal Microarray (CMA): _____
 MRI brain: _____
 MRI (other): _____

CT brain: _____
 CT (other): _____
 Muscle biopsy: _____
 Ultrasound: _____
 X-Ray: _____

METABOLIC FINDINGS • Attach relevant lab reports and values.

☐ Abnormal newborn screen
 Specify: _____

Abnormal metabolic profile

(please check each metabolite outside normal limits)

☐ Acylcarnitine _____
☐ Acylglycines _____
☐ Amino Acids _____
☐ Amylase _____
☐ Biotindase _____
☐ Carnitine _____
☐ Cerebrospinal fluid _____
☐ Coenzyme/enzyme activity _____
☐ Creatine phosphokinase (CPK) _____
☐ Essential fatty acids _____
☐ Folate _____
☐ Hepatic Transaminase _____
☐ Homocysteine _____
☐ Hormones _____
☐ Ketones _____
☐ Lactic acidosis _____
☐ Lipase _____

☐ Lipoproteins _____
☐ Lysosomal enzymes _____
☐ Mucopolysaccharides _____
☐ Oligosaccharides _____
☐ Porphyrin _____
☐ Pterins _____
☐ Purines _____
☐ Pyrimidine _____
☐ Pyruvate _____
☐ Serum alpha fetoprotein (AFP) _____
☐ Sterols/Oxysterols _____
☐ Transferrin _____
☐ Uric acid _____
☐ Very long chain fatty acids (VLCFA) _____

Abnormal vitamin levels

(please check each vitamin measuring outside normal limits)

☐ Copper _____
☐ Magnesium _____
☐ Manganese _____
☐ Vitamin B6 _____
☐ Vitamin B12 _____

☐ Vitamin D _____
☐ Zinc _____
☐ Other _____

Other metabolic features

☐ Abnormal cerebrospinal fluid (CSF) studies _____
☐ Abnormal glycosylation _____
☐ Abnormal mitochondrial respiratory chain activity _____
☐ Hyperammonemia _____
☐ Hyperbilirubinemia _____
☐ Hyperglycemia _____
☐ Hyperlipidemia _____
☐ Hypoglycemia _____
☐ Hypolipidemia _____
☐ Plasma _____
☐ Urine _____
☐ Lactic Acidosis _____
☐ Metabolic Acidosis _____
☐ Methylmalonic aciduria _____
☐ Methylmalonic acidemia _____

ADDITIONAL NOTES

If additional space is required, please continue your response below. **Include a continued notation on the other or specify line.**

